Table 3

Comparison of the patients with and without manic switch.

Treatment characteristicsManic switch present (n=58)Manic switch absent (n=65)t/Z/χ2P-value
n (%)
+AD-type
 SSRI33 (42.85)44 (57.15)3.642a0.314
 TCA8 (40.00)12 (60.00)
 Venlafaxine2 (33.33)4 (66.67)
 Mirtazapine4 (20.0)16 (80.00)
Duration of AD use
 ≤3 months9 (100)0 (0)12.083a0.006*
 3-6 months17 (44.7)21 (55.3)
 6-12 months13 (46.4)15 (53.6)
 >12 months19 (39.6)29 (60.4)
+Combined agent
 Lithium21 (37.5)35 (62.5)2.422a0.302
 AC4 (25.0)12 (75.0)
 AP0 (0)4 (100)
Diagnosis
 Bipolar I47 (42.35)64 (57.65)0.002a0.964
 Bipolar II5 (41.66)7 (58.34)
Mean dose (SD), (mg)
++++SSRI22.98 (9.4)21.73 (8.76)0.600b0.550
+++TCA103 (97.99)118 (103)0.439c0.330
+++Venlafaxine75 (-)100 (43)1.095c0.273
+++Mirtazapine32.86 (6.88)30.22 (18.76)0.276c0.782
++++MED22.68 (9)22.12 (12)0.290b0.772
Mean duration (months)5.65 (6.34)13.12 (14.36)2.878c0.004*
  • Chi Square, Chi Square with Yates Correction,

  • + Fisher Exact Chi Square,++Chi Square,

  • +++ Mann Whitney U test,

  • ++++ Student t Test,

  • a X2 value,

  • b t value,

  • c Z value, AD - antidepressant, SSRI - selective serotonin reuptake inhibitors, TCA - tricyclic antidepressants, AC - anticonvulsant, AP - antipsychotic, MED - mean equivalent dose, NS - not Significant (p>0.05),

  • * p<0.05 statistically significant.